^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RET-PTC1 rearrangement

    i
    Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1, PTC1, Patched Ho
    Entrez ID:
    5979; 5727
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    10ms
    Whether Detection of Gene Mutations Could Identify Low- or High-Risk Papillary Thyroid Microcarcinoma? Data from 393 Cases Using the Next-Generation Sequencing. (PubMed, Int J Endocrinol)
    The size of the tumor has a significant correlation with its aggressive characteristics. PTMC with a diameter of ≤5 mm should be distinguished and targeted as a unique subset for specialized treatment.
    Journal • Next-generation sequencing
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • TERT (Telomerase Reverse Transcriptase) • NCOA4 (Nuclear Receptor Coactivator 4)
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • RET mutation • RET rearrangement • RET-PTC1 rearrangement • TERT mutation • TERT promoter mutation
    1year
    RET/PTC rearrangement in papillary thyroid carcinoma arising in malignant struma ovarii with abdominal wall metastasis and cervical thyroid gland: a case report and review of the literature. (PubMed, Thyroid Res)
    In light of these findings, malignant struma ovarii might yield a clue to cervical thyroid carcinoma, and the molecular analysis could provide valuable information for understanding the underlying mechanism, tumor clinicopathological behaviors, and prognosis.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF mutation • RAS mutation • RET mutation • RET rearrangement • RET-PTC1 rearrangement
    1year
    PAPILLARY THYROID CANCER DERIVED CELL LINES ARE MORE RESISTANT TO THE GENOTOXIC EFFECT OF BISPHENOL A THAN CONTROL THYROID CELLS (ATA 2023)
    We conclude that resistance to low concentrations of BPA cytotoxic effects on mutated thyroid cells is due, at least in part, to DNA damage. Even doses of BPA that are considered acceptable can be genotoxic for normal thyroid cells but affect less thyroid mutated cells that can therefore be selected for and contribute to the emergence of thyroid tumors.
    Preclinical • Late-breaking abstract
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • RET rearrangement • RET-PTC1 rearrangement
    2years
    WHETHER DETECTION OF GENE MUTATION COULD IDENTIFY THE LOW‐ OR HIGH‐ RISK PAPILLARY THYROID MICROCARCINOMA? THE DATA FROM 393 CASES USING NEXT GENERATION 77‐GENE‐PANEL SEQUENCING (ATA 2022)
    Though it was predominant in PTMC in our study, BRAFV600E mutation could not be a valuable tool to identify high‐risk or tumor progression of PTMC, from a clinical point of view. Instead, tumor size was closely related to aggressiveness. PTMC with ≤5mm should be regarded as a special group and treated specially.
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • RET (Ret Proto-Oncogene) • TERT (Telomerase Reverse Transcriptase) • NCOA4 (Nuclear Receptor Coactivator 4)
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • RET mutation • RET rearrangement • NRAS Q61 • NRAS Q61R • RET-PTC1 rearrangement • TERT mutation • TERT promoter mutation • TERT mutation + BRAF V600E